New Leaf Venture Partners, L.L.C. Crinetics Pharmaceuticals, Inc. Transaction History
New Leaf Venture Partners, L.L.C.
- $96.9 Million
- Q3 2024
A detailed history of New Leaf Venture Partners, L.L.C. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, New Leaf Venture Partners, L.L.C. holds 141,000 shares of CRNX stock, worth $7.56 Million. This represents 7.43% of its overall portfolio holdings.
Number of Shares
141,000
Previous 141,000
-0.0%
Holding current value
$7.56 Million
Previous $6.32 Million
14.05%
% of portfolio
7.43%
Previous 7.69%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$337 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$334 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$315 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$265 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$239 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.88B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...